Loading stock data…
$1.72+0.01 (+0.58%)
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.
Aptevo Therapeutics Inc. in the Healthcare sector is trading at $1.72. Wall Street consensus targets $25.50 (2 analysts), implying a +1382.6% move over the next 12 months. The stock is currently near its 52-week low of $1.37, remaining 64.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$6.44M↑ | -$6.84M↓ | -$6.00M↑ | -$7.61M↓ | -$6.23M |
| Net Income | -$6.36M↑ | -$6.70M↓ | -$5.81M↑ | -$7.55M↓ | -$6.20M |
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using A...